For type 2 diabetes mellitus. ANDA 203769, held by Sciegen Pharms. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 203769 (Metformin Hydrochloride), held by Sciegen Pharms, was first approved by FDA on Sep 11, 2013, with 6 approved supplements and 0 published complete response letters.
Metformin Hydrochloride Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 11, 2013 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride850MG · tablet;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride1GM · tablet;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride625MG · tablet;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride750MG · tablet;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 36Labeling · Standard review | Approved | None posted |
| May 5, 2020 | Supplement 18Labeling · Standard review | Approved | None posted |
| Feb 22, 2019 | Supplement 12Labeling · Standard review | Approved | None posted |
| Feb 22, 2019 | Supplement 9Labeling · Standard review | Approved | None posted |
| Dec 2, 2014 | Supplement 3Manufacturing | Approved | None posted |
| Mar 20, 2014 | Supplement 1Manufacturing | Approved | None posted |
| Sep 11, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters